ArticleCalcified tissue international2026
Association of Serum Parathyroid Hormone Levels with All-Cause and Cause-Specific Mortality Among U.S. Adults, with a Focus on the Parathyroid Hormone Levels Within the Normal Range: a Population-Based Cohort Study from NHANES 2003-2006.
Article in Calcified tissue international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
This study investigated the correlation between serum parathyroid hormone (PTH) levels and the risks of all-cause and cause-specific mortality, with specific focus on the association between serum PTH levels within the normal range and mortality risk. This prospective cohort study included 6633 non-hypoparathyroid participants (aged ≥ 20 years) from the National Health and Nutrition Examination Survey 2003-2006. We employed restricted cubic splines to depict the dose-response relationship between serum PTH and the risks of mortality. Multivariate Cox proportional hazards models were used to calculate the hazard ratios (HR) and 95% confidence intervals (95%CI). Among the 6633 participants, 1309 died during follow-up, including 437 cardiovascular deaths, 316 cancer-related deaths, and 556 non-cardiovascular-non-cancer deaths. Restricted cubic splines suggested that ideal outcomes were observed with serum PTH at the lower level of the normal range (18-41 pg/ml). Compared with participants in the low-normal PTH range (18-41 pg/ml), those in the high-normal range (42-74 pg/ml, accounting for 40.4% of the entire normal range) had 22% (HR:1.22,95%CI 1.02-1.46) and 66% (HR:1.66,95%CI 1.20-2.30) increased risks of all-cause and cardiovascular mortality. Similarly, participants in the high PTH range (> 74 pg/ml) had 34% (HR:1.34,95%CI 1.08-1.68), 59% (HR:1.59,95%CI 1.03-2.46) and 44% (HR:1.44,95%CI 1.02-2.04) increased risks of all-cause, cardiovascular and non-cardiovascular-non-cancer mortality. Among U.S. adults, high-normal and high PTH levels were both associated with higher risks of all-cause and cardiovascular mortality. Further studies are needed to evaluate the clinical implications of screening and management for this high-risk population, especially those with high-normal PTH levels, who account for a substantial proportion of the normal-range population but are usually receiving insufficient clinical attention.
Indexed as
Identifiers
42747487What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.